Triumeq briefly improved motor function in a TDP-43 ALS mouse model
Original source
Evaluation of triumeq treatment on a TDP-43 mouse model of amyotrophic Lateral sclerosis. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Mouse
Related topics
Triumeq produced a significant early improvement in motor function in mice with TDP-43-related ALS-like disease. The treatment did not improve other measures of disease progression or extend the disease endpoint, but it altered some inflammation-related gene activity.
Why this matters
The findings support further study of Triumeq and TDP-43-linked inflammation in ALS. This was an animal study, so it does not show that Triumeq benefits people with ALS or change current treatment.
Limitations and context
The study used a specific, doxycycline-controlled TDP-43 mouse model. The motor improvement was modest and temporary, and other disease measures were unchanged. The results do not establish safety or effectiveness in people.